GenEmbryomics
2 known investors
GenEmbryomics provides comprehensive preimplantation genetic screening of IVF embryos using whole genome sequencing, screening for chromosome abnormalities, mosaicism, and thousands of inherited and new genetic mutations. It serves patients and families undergoing IVF, delivering reports to help select embryos with the lowest genetic disease risk.
Also known as GenEmbryomics Pty Ltd
Founders & leadership
Investors · 2
Company profile
researched Aug 2026GenEmbryomics is a reproductive genomics company whose flagship offering, marketed as Panacea GenomeScreen and described as PGT-WGS (preimplantation genetic testing with whole genome sequencing), is positioned as a single test combining the functions of conventional PGT-A (aneuploidy), PGT-M (monogenic/single-gene disorders) and PGT-SR (structural rearrangements) while additionally screening 3,200+ genes for inherited and de novo mutations, with expanded gene options available. The company states the test sequences both parental and embryonic DNA and identifies mutations associated with severe and fatal genetic conditions, and its website labels the PGT-WGS offering as for research use only.
The testing workflow described by the company begins with a patient raising the test with their IVF clinic; cells are biopsied from embryos at day 5 or 6 of development and sent to a genetics laboratory, where DNA is extracted, amplified and sequenced. GenEmbryomics says it works with partner facilities for laboratory work and applies a proprietary bioinformatics pipeline built for embryo analysis, evaluating variants and gene expression to assess viability, with results returned to the ordering physician in roughly three weeks as a confidential report used with the clinic and genetic counsellor to inform embryo selection. The company also references use of next-generation sequencing platforms and AI techniques in its analysis.
GenEmbryomics indicates PGT-WGS is applicable to any IVF patient and highlights specific situations such as recurrent unexplained pregnancy loss, multiple failed IVF cycles or transfers, a prior pregnancy affected by a genetic disorder, abnormal carrier screening results, family history of a genetic condition or chromosome abnormality, advanced maternal age over 35, advanced paternal age over 40 (elsewhere stated as male partners above 37), and use of donor gametes from older donors.
Founding story
Nick Murphy founded GenEmbryomics after a career in genetics research applied to assisted reproductive technology, immunogenetics and polygenic risk assessment, and with more than ten years of experience in the IVF industry, launching the company to develop genomic testing for embryo screening.
Business model
GenEmbryomics sells genetic screening of IVF embryos that is ordered through fertility clinics and providers rather than directly by patients; testing is arranged via the patient's IVF clinic, laboratory work is performed with partner facilities, and a report is delivered to the treating physician. The company also frames its offering as giving laboratories the tools to deliver genetic screening to IVF clinicians and their patients.
Traction
A third-party company database lists GenEmbryomics with 1-10 employees. Company materials state partnerships with Qualio and Compliancy Group for quality and compliance standards.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
GenEmbryomics positions PGT-WGS as the first whole genome sequencing-based assay for evaluating embryonic genetic health and contrasts it with standard preimplantation genetic testing, which it describes as detecting chromosome copy-number abnormalities and mosaicism but missing sequence-level genetic disease. Company materials describe it as a global leader in embryo and parent whole genome sequencing.
GenEmbryomics differentiates on breadth of analysis: whole genome sequencing of embryos and parents in one assay covering aneuploidy, mosaicism, structural rearrangements, inherited monogenic disease and de novo mutations across 3,200+ genes, versus what it characterizes as partial testing from other providers.
Technology
The company uses next-generation sequencing to produce whole genome sequences of embryonic and parental DNA, combined with a proprietary bioinformatics pipeline designed for embryo analysis that evaluates variants and gene expression to assess viability, and references advanced AI techniques. The PGT-WGS assay covers aneuploidies, mosaicism, chromosomal structural rearrangements, inherited monogenic conditions and de novo mutations, screening 3,200+ genes with expanded panels available. Sample processing involves day-5 or day-6 embryo biopsy, DNA extraction, amplification and sequencing, with reports returned in about three weeks.
Go-to-market
IVF patients and couples undergoing assisted reproduction, reached through fertility clinics, IVF providers and genetic counsellors; the company also addresses laboratories that deliver screening services to IVF clinicians.
Geography
Company contact details list an address at 580 California St, 12th Floor, San Francisco, California 94104, with a US toll-free phone number; a startup directory profile lists Melbourne, Victoria, Australia as the company location and AUD as its currency.
History
The company is listed as founded in January 2019 with a Melbourne, Victoria, Australia location on a startup directory profile, and its contact page lists an address in San Francisco, California. Its governance structure includes a board of directors chaired by Paul Viney (Managing Director of venture capital firm Braddon Capital), with founder Nick Murphy as Managing Director, reproductive genetics researcher Santiago Munn\u00e9 as non-executive director, and Nick Burrows as independent non-executive director and audit and risk committee chair. The leadership team also includes Kyle Day (Head of Technology) and Ellissa Marshall (Governance Officer).
Risks & controversies
The company's website states that its PGT-WGS/Panacea GenomeScreen offering is for research use only, and notes that PGT is a screening rather than diagnostic test requiring follow-up diagnostic testing with a provider.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsGenEmbryomics states it partners with Qualio and Compliancy Group to support quality and compliance standards.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- GenEmbryomicsgenembryomics.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does GenEmbryomics do?
- GenEmbryomics offers whole genome sequencing-based preimplantation genetic testing (PGT-WGS) for IVF embryos and parents.
- Who are GenEmbryomics's investors?
- GenEmbryomics's investors include Artesian, MedTech Actuator.